Entera Bio shares hold Buy rating on OXM study success By Investing.com

On Friday, H.C. Wainwright maintained a Buy rating on shares of Entera Bio (NASDAQ:), with a price target of $10.00. The firm’s stance comes after Entera Bio, in collaboration with OPKO Health (NASDAQ:OPK), announced earlier this week positive top-line results from their research on a novel oral treatment for obesity and metabolic disorders.

The collaborative research focuses on combining OPKO’s long-acting oxyntomodulin (OXM) analog with Entera’s N-Tab technology to develop the first oral dual agonist GLP-1/glucagon peptide. This potential once-daily treatment aims to address obesity, metabolic, and fibrotic disorders. OXM is a peptide hormone that originates in the small intestine, known for its appetite suppression and weight loss induction properties.

Entera Bio and OPKO Health have successfully completed in vivo proof-of-concept pharmacokinetic and pharmacodynamic (PK/PD) studies using rodent and pig models. The studies achieved their objectives, demonstrating significant systemic exposure to oral OXM after a single dose in both animal models.

The analyst from H.C. Wainwright reiterated the positive outlook based on these findings, confirming the Buy rating and the 12-month price target for Entera Bio’s stock. The continued development of this oral therapy could represent a significant advancement in the treatment of obesity and related disorders.

In other recent news, Entera Bio Ltd . and OPKO Health, Inc. reported positive preliminary results from their joint research into an orally delivered treatment for obesity and related metabolic disorders. The study focused on a long-acting oxyntomodulin (OXM) analog combined with Entera’s N-Tab™ technology.

In vivo studies in rodent and pig models indicated significant systemic exposure and a favorable pharmacokinetic profile for the oral OXM after a single dose. In a glucose tolerance test on rats, oral OXM significantly reduced plasma glucose levels post-glucose administration compared to a placebo, supporting the continued development of the treatment.

Simultaneously, Entera Bio’s shareholders approved key proposals, including the election of Miranda Toledano and Yonatan Malca to the company’s Board of Directors for a three-year term. The shareholders also approved a one-time compensation grant for CEO Miranda Toledano, revised compensation terms for non-executive directors, and an amendment to the company’s 2018 Equity Incentive Plan, which includes an increase in the number of shares issuable by 1,788,515 shares.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.